Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719561 | 0.85 | SLC7A5 (0.38) | DPP4CYP2C9CYP2C19 | |
| SCHEMBL18137456 | 0.79 | DPP4 (0.59) | DPP4MAPK1HSP90AA1KDM4EMEN1 | |
| SCHEMBL5488554 | 0.79 | CYP2C9 (0.47) | MAPK1KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL27939903 | 0.79 | CA12 (0.38) | DPP4CYP2C19 | |
| SCHEMBL14466766 | 0.78 | CYP2C9 (0.51) | DPP4MAPK1HSP90AA1CYP2C9CYP2C19 | |
| SCHEMBL18137575 | 0.77 | DPP4 (0.56) | DPP4MAPK1HSP90AA1KDM4EMEN1 | |
| SCHEMBL20703109 | 0.76 | CYP2C9 (0.50) | DPP4MAPK1HSP90AA1CYP2C9CYP2C19 | |
| SCHEMBL20703488 | 0.75 | CYP2C9 (0.49) | DPP4MAPK1HSP90AA1KDM4ECYP2C9 | |
| SCHEMBL29382818 | 0.75 | CYP2C19 (0.69) | CYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL28383608 | 0.75 | CHEK2 (0.58) | HSP90AA1KDM4ECYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3447058-B1 | NOVEL BROAD-SPECTRUM BETA-LACTAMASE INHIBITOR | WUHAN VISION PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-10479805-B2 | Beta-lactamase inhibitor | WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-11-19 | — | — | US | disclosed |
| US-20190048027-A1 | BETA-LACTAMASE INHIBITOR | WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048027-A1 | BETA-LACTAMASE INHIBITOR | ALPI, MGAM, LCT | DPP4 821/4885MAPK1 4484/4885HSP90AA1 1596/4885 |
| US-10479805-B2 | Beta-lactamase inhibitor | ALPI, MGAM, LCT | DPP4 821/4885MAPK1 4484/4885HSP90AA1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.